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Abstract
Background: Most women with breast cancer experience a progressive weight gain during and after treatment.
Obesity is associated with an increased risk of recurrence, contralateral breast cancer, and death. Physical activity
after cancer diagnosis has been reported to have positive effects on body composition and quality of life. We
present the protocol of the InForma study, a trial testing the efficacy of an intervention on weight loss (≥5 % of the
baseline body weight) in a group of overweight or obese breast cancer survivors.
Methods/design: This is a four-arm randomized controlled trial. Patients will receive a 6-month intervention and
be followed for a further 18 months. Intervention is designed to improve adherence to a healthy diet and/or to
increase physical activity, taking advantage of a wrist-based activity monitor. Participants will be recruited among
overweight or obese breast cancer patients treated at the European Institute of Oncology, after completion of
eventual adjuvant chemotherapy and/or radiotherapy. It is envisaged that 260 patients will be randomized into four
arms: Dietary Intervention; Physical Activity Intervention; Physical Activity and Dietary Intervention; and Less
Intensive Intervention. Women will be offered individualized counseling consisting of face-to face discussion and
phone calls in addition to group meetings. A motivational interviewing approach will be used to encourage health
behavior change. All participants will be given a pedometer device to monitor their physical activity. Participants’
dietary intake will be repeatedly assessed using a validated food frequency questionnaire. Participants’ quality of life
and anxiety will be assessed with the Functional Assessment of Cancer Therapy-Breast and the State-Trait Anxiety
Inventory questionnaires. Blood samples will be collected at baseline and follow-up visits to assess lipid and
hormone profiles. Body composition will be repeatedly assessed using bioelectrical impedance vector analysis for
identifying changes of fat and fat-free mass. Women allocated to the less intensive intervention arm will be
considered as the control group.
Discussion: While there is a rising concern about the role of obesity in cancer recurrence and survival, this trial
with its multi-arm design, motivational approach and use of a pedometer device will provide important insights
regarding the most effective approach in promoting weight control in breast cancer survivors.
Trial registration: ISRCTN53325751 (registration date: 16 October 2015); ClinicalTrials.gov NCT02622711 (registration
date: 2 December 2015).
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Background
Breast cancer is the most frequently diagnosed form of
cancer and the leading cause of cancer death among
women worldwide, with an estimated 1.7 million new
cases and 521,900 deaths in 2012 [1]. According to the
association of Italian Cancer Registries [2], breast cancer
is also the most common cancer in women in Italy with
581,373 newly diagnosed cases in 2010. The estimated
incidence is stable and mortality is decreasing mainly
due to advances in diagnosis and treatment. Conse-
quently survival from breast cancer has improved, and
currently about 87 % of breast cancer patients in Italy
survive more than 5 years [2].
Modifiable lifestyle factors such as obesity, physical in-
activity and excessive alcohol consumption are estab-
lished risk factors for the development of, and death
from, breast cancer [3, 4]. There is also accepted evi-
dence that, after a diagnosis of breast cancer, being over-
weight or obese is associated with an increased risk of
breast cancer relapse, death [5, 6], or second primary
contralateral breast cancer [7–9]. In a recent meta-ana-
lysis including more than 200,000 patients with breast
cancer, Chan et al. [10] demonstrated a 41 % increase in
overall mortality in obese and 7 % in overweight women
and a 35 % increase in breast cancer-specific mortality in
obese women and 11 % in overweight women, as com-
pared with patients who had normal weight at diagnosis.
Most women experience a progressive weight gain
during and after treatment for breast cancer [11, 12] due
to the changes in hormone levels and body composition
associated with treatment. Weight gain usually ranges
from 2–6 kg in the first year following diagnosis, but
greater gains are also common [13]. Chemotherapy is as-
sociated with weight gain due to a reduced metabolism
and the subsequent induction of menopause increasing
the likelihood of weight gain [13]. Moreover treatment-
related side effects, duration of treatments and psycho-
logical distress may affect diet and physical activity
patterns compromising energy balance in ways that pro-
mote weight gain.
High body mass index (BMI) results in an increased
production of hormones (estrogens, insulin, leptin), and
pro-inflammatory cytokines, which have, in turn, been
associated with breast cancer risk [14, 15]. In fact, estro-
genic stimulation promotes breast cancer pathogenesis
and tumorgenesis, while insulin and leptin exhibit prolif-
erative, mitogenic, and anti-apoptotic activities in mam-
mary cells, thus promoting tumor growth [16]. High
circulating estrogen levels are associated with increased
risk of breast cancer recurrence [17, 18].
Alongside this, physical inactivity represents a leading
cause of death worldwide [19]. Regular physical activity
yields a wide range of health benefits, because it is asso-
ciated with healthier levels of circulating hormones
(insulin, leptin and insulin-like growth factor (IGF)-1
and IGF-3, estrogens and androgens) [20, 21] as well as
possibly strengthening the immune system [22]. More-
over physical activity after breast cancer diagnosis has
also been reported to have positive effects on body com-
position, psychological outcomes, and quality of life
(QoL) [23].
The number of trials of weight loss interventions in
breast cancer is increasing, but a demonstration of
their benefit on breast cancer outcome is limited [24].
Weight loss resulting from intentional increased phys-
ical activity and caloric restriction can improve hor-
monal status, quality of life, and physical functioning
among obese and overweight breast cancer survivors
[9, 24, 25]. Regular physical activity and healthy diet-
ary habits are important factors for reducing the risk
of cancer recurrence and mortality, as well as
lifestyle-related chronic conditions [7, 26]. Few inter-
vention trials in breast cancer survivors, integrating
physical activity and dietary intervention have been
initiated or conducted so far [24, 27, 28].
Despite the accumulating evidence of the detrimental
effect of physical inactivity and being overweight on
breast cancer risk and risk of breast cancer recurrence,
weight control and physical activity counseling are not
yet current practice. Clinicians typically try to advise pa-
tients to change their lifestyle habits using a directing
style but this approach is often ineffective. Patients often
seem ambivalent or unmotivated in respect to these
messages and, in turn, generate resistance or passivity.
Motivational interviewing is an alternative approach to
discussing behavior change that fosters a constructive
specialist-patient relationship and leads to better out-
comes for patients. This intervention, aimed at encour-
aging positive health behavior changes within a medical
setting, is promising [29], and it can help individuals to
enhance adherence to diet and exercise modification
programs [30].
The prognostic role of body mass index has been pre-
viously assessed on the outcome of a consecutive series
of women treated at our institution (the European Insti-
tute of Oncology (IEO), Milan, Italy) for an aggressive
form [estrogen receptor/human epidermal growth factor
receptor 2 (ER-/HER2)-positive] of breast cancer. In
these patients, obesity was significantly associated with
the risk of developing distant metastases and with worse
overall survival [31].
Given the above considerations, our aim is to evaluate
the effect of a 6-month intervention on weight loss in a
group of overweight or obese women treated for early
breast cancer. The intervention is designed to improve
adherence to a healthy diet or/and to increase physical
activity and decreased sedentary time, taking advantage
of a wrist-based activity monitor (pedometer device).
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Methods/design
Study design
The present study (InForma) was designed as a mono-
institutional randomized controlled four-arm parallel-
group trial. Randomized patients will receive a 6-month
intervention and will be followed for further 18 months
(Fig. 1).
Study population and randomization
Potential study participants will be recruited among all
overweight or obese breast cancer patients treated at the
IEO after breast cancer treatments (surgery, chemotherapy
and/or radiation therapy) have been completed. Women
undergoing hormone therapy will be eligible for the study.
Groups of eligible participants will be invited at IEO for
further eligibility assessment and enrolment. On arrival,
they will receive a progressive number from the front desk
receptionist. After an information meeting, they will be in-
vited to sign all the study documents (informed consent
form, privacy disclosure). Height, weight, waist and hip
circumferences, and body composition will be measured.
Participants who are eligible will receive the study ques-
tionnaires to be filled in. They will then be called following
their random arrival number and be allocated in a 1:1:1:1
Fig. 1 Study flowchart
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ratio to one of the four intervention arms: Dietary
Intervention (DI); Physical Activity Intervention (PAI);
Physical Activity and Dietary Intervention (PADI); or
Less Intensive Intervention (LII) following a pre-established
randomization list (Fig. 1). The randomization list was cre-
ated using a computer random number generator and
securely kept by a study collaborator not involved at the
front desk. Randomization is not stratified, but blocks of 20
were created to achieve balance in the allocation of partici-
pants to the four treatment arms. The randomization list is
not known to the front desk receptionist (administrative
staff) who provides the progressive number that will be
matched with the randomization number at the end of the
information meeting. Randomization will be made by a
member of the InForma study team (dietician or physio-
therapist). This to ensure that allocation cannot be guessed
before registration. Allocation is fixed and cannot be chan-
ged after randomization.
Study outcomes
The main aim of the study is to evaluate the impact of a
6-month intervention program on body weight change
(weight loss ≥5 % of the baseline body weight) in over-
weight or obese breast cancer survivors.
As secondary outcomes, we will further examine the
impact of the intervention on long-term weight control
or maintenance, physical activity and inactivity levels,
dietary intake, health status, and quality of life. We will
also examine the effect of intervention on blood lipid
profile [total, high-density lipoprotein (HDL), low-density
lipoprotein (LDL) and very low density lipoprotein
(VLDL) cholesterol and triglycerides] and on estradiol, C-
reactive protein (CRP), insulin, and glucose at 6-, 12- and
24-month visits.
Inclusion criteria
The study will be open to overweight or obese (BMI > 25
kg/m2) women, aged 18 years or older, who have been
treated for a histologically confirmed, invasive, non-
metastatic breast cancer and have completed their main
cancer treatment (surgery, chemotherapy, radiation ther-
apy) for more than 6 months.
Only those women who are able to participate in the
intervention, who agree to wear the wrist-based activity
monitor during the study period, and who sign the in-
formed consent form and the privacy disclosure, will be
enrolled.
Exclusion criteria
Women satisfying any of the following criteria will not
be eligible for the study: previous severe medical condi-
tion(s); advanced age impeding their adherence to the
planned study schedules; contraindications to exercise
due to any heart condition, stroke, chest pain during
activity or rest; severe hypertension and any orthopedic
complications that would prevent optimal participation
in the physical activities prescribed; unable to walk for
exercise (self-reported); symptoms of alcohol or sub-
stance dependence.
Other non-medical exclusion criteria are: lack of trans-
portation to the study location over the study period;
plans to move away from Lombardy or to be inaccessible
for more than 3 weeks during the intervention period.
Intervention
The principal aim of the intervention is to promote weight
loss through diet and physical activity alone or in combin-
ation. The target goal is a 5 % weight loss 6 months after
randomization. Participants will be followed up for a fur-
ther 18 months and secondary outcome assessments will
be made at 12 and 24 months (Table 1).
Baseline assessment will be made for all participating
women, prior to randomization in one of the four inter-
vention arms (DI, PAI, PADI, and LII). All participants
must wear the wrist-based activity monitor during the 6-
month intervention period (day and night).
Participants randomized to one of the three interven-
tion arms (DI, PAI, and PADI) will be given individual-
ized counseling based on their lifestyle habits to reduce
their weight. The motivational interviewing approach
will be used to discuss behavior change that fosters a
constructive specialist-patient relationship which could
lead to better body weight control for the patients.
The intervention will begin with an intensive phase
consisting of monthly contacts: three face-to-face meet-
ings, one group meeting and two motivational phone
calls. The group sessions are planned for closed groups
of an average of ten women per arm and will consist of
a motivation and information session to discuss strat-
egies and to reinforce guidance. The participants may in-
vite a caregiver or a relative during the group meeting.
The meeting aims to offer a caring and supportive envir-
onment where its members support each other and ex-
plore new strategies to create long-lasting positive
changes. At baseline, their requirement for weight main-
tenance will be calculated using the Schofield equation
[32] and then multiplied by their current physical activ-
ity level before applying a caloric restriction of about
500–1000 kilocalorie (kcal)/day [33, 34].
Individualized goals will be set for all participants in-
cluded in the three intervention arms to promote weight
loss. These goals will be verified at each contact and
workable solutions will be proposed in case of specific
problems. The contents of all contacts are presented in
Table 2.
From 6 months onward, participants will be monitored
by phone calls during which the strategies and guidance
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discussed in the face-to-face sessions will be repeated
and reinforced.
DI arm
The overall content of the intervention consists of an
individualized diet modification proposal that will pro-
mote an energy deficit. The educational components of
healthy eating habits will be based on national and
international recommendations [4, 35]. Strategies and
approaches to be applied include self-monitoring of food
intake; realistic goal-setting, using behavior-specific goals
and a step-wise approach to promote self-efficacy; ad-
dressing body image concerns and prevention of cancer
relapse.
Safe weight loss should be achieved through a bal-
anced diet according to the Italian dietary reference in-
takes [36]. Key strategies will emphasize the reduction of
energy density by low-energy dense foods (e.g., water-
and fiber-rich vegetables and fruits), limiting the intake
of foods and beverages high in fat and added sugar, and
limiting portion sizes.
Each goal will be stated and verified at each contact
(reduce the portion size of cheese instead of normal por-
tion size; choose fresh fish, instead of preserved fish,
freshly squeezed lemon juice in water, instead of soft
drinks). Participants will also be advised not to fall too
far below their goal to support nutritional adequacy.
PAI arm
The PAI will be designed on an individualized level,
whereby specific activities are planned based on capabil-
ities, lifestyle pattern and preferences so as to increase
physical activity and to reduce sedentary time. Realistic
and achievable goals will be set working toward short-
term and long-term goals. A priority will be placed on
regular planned aerobic exercise, since this creates an
energy deficit that is much greater per unit of time than
strength training. The general exercise prescription
planned will be of low to moderate intensity, regular fre-
quency, involving aerobic, resistance or mixed exercise
types. The physical activity targets are: to be moderately
physically active, equivalent to brisk walking for at least
30 min a day (short-term goal); to do purposeful exercise
at a moderate level of intensity at least 60 min/day or
≥30 min of vigorous physical activity every day (long-
term goal) [34, 37]. Reasonably, the initial goal will be to
plan and implement daily purposeful mild to moderate
exercise for a minimum of at least 10 min/day with a
stepwise increase in time and intensity that will be eval-
uated and modified at each contact. Women who exer-
cised at a higher level than 10 min/day at baseline will
be instructed to aim for an incrementally greater goal of
daily exercise and to plan to increase intensity as toler-
ated. Participants will wear the wrist-based activity
monitor and they will be instructed to count the total
number of steps to improve their self-monitoring and to
reduce sedentary time.
Personalized goals will be set to increase physical ac-
tivity. Each goal will be stated and verified at each con-
tact (use public transportation to go to work instead of
the car; use the stairs instead of using the elevator, check
the wrist-based activity monitor). Safe increased physical
activity should be recommended through a program tai-
lored to individual characteristics. Participants will be
Table 1 Study assessments
Assessments Instrument Visits
Baseline 6-month 12-month 24-month
Total, HDL, LDL and VLDL cholesterol, triglycerides,
estradiol, insulin, glucose and C-reactive protein
Blood test √ √ √
Heighta, weight, waist and hip circumference,
body mass index, waist-to-hip ratio
Calibrated scales, stadiometer,
tape measure
√ √ √ √
Body composition (including total body water (TBW),
body cell mass (BCM), extracellular water (ECW),
fat-free mass (FFM), fat mass (FM) and percentage
fat mass (% FM)
Bioelectrical impedance vector
analysis (BIVA) (Nutrilab device,
AKERN Srl – Italy)
√ √ √ √
Dietary target 24 hr recalls and/or food diary √b √
Steps Pedometer-like device √b √
Diet Food Frequency Questionnaire (FFQ) √ √ √
Quality of life Functional Assessment of Cancer
Therapy- Breast (FACT-B)
√ √ √
Mood State-Trait Anxiety Inventory (STAI) √ √ √
Physical activity International Physical Activity
Questionnaire (IPAQ)
√ √ √
aHeight will be assessed only at baseline
b24 hr recalls and/or food diary and the pedometer-like device will be used during the intervention to monitor individualized goals
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Table 2 Delivery and contents of the 6-month intervention visits for participants randomized to the intervention arms: Dietary Intervention (DI); Physical Activity Intervention
(PAI); Physical Activity; and Dietary Intervention (PADI)
Contact 1 Contact 2 Contact 3 Contact 4 Contact 5 Contact 6
Contact Face-to-face Telephone Group meeting Face-to-face Telephone Face-to-face
Time line 1 month (following
baseline assessment)
2 months 3 months 4 months 5 months 6 months
Duration 30 min 15 min 90 min 30 min 15 min 30 min
Who delivers Dietician and/or
physiotherapist
Dietician and/or
physiotherapist
Psychologist, dietician and
physiotherapist
Dietician and/or
physiotherapist
Dietician and/or
physiotherapist
Dietician and/or
physiotherapist
Social support - - Invited friend/partner/family
member
- - -
Motivational
approaches
1/2 week diet/activity
diaries assessment
Identify perceived diet/
activity challenges
Coping and provide
opportunities to learn from
each other
1/2 week diet/activity
diaries assessment
Identify perceived diet/
activity challenges
1/2 week diet/activity
diaries assessment
Identify perceived diet/
activity challenges
Provide feedback and
encouragement
Review and discuss members’
goal evaluations
Identify perceived diet/
activity challenges
Provide feedback and
encouragement
Identify perceived diet/
activity challenges
Identify motivations,
confidence, ambivalence
regarding lifestyle change
Revaluate motivations,
confidence, ambivalence
regarding lifestyle change
Evaluate and discuss members’
motivation to change
Provide feedback and
encouragement Revaluate
motivations, confidence,
ambivalence regarding
lifestyle change
Revaluate motivations,
confidence, ambivalence
regarding life style change
Provide feedback and
encouragement Revaluate
motivations, confidence,
ambivalence regarding
lifestyle change
Informing change Healthy eating and activity
principles Portion size
Discuss experience of
changing diet and activity
referring back to perceived
challenges at previous visit.
Provide general advice for
psychological well-being and
health promotion
Discuss experience of
changing diet and activity
referring back to perceived
challenges at previous visit.
Discuss experience of
changing diet and activity
referring back to perceived
challenges at previous visit.
Discuss experience of
changing diet and activity
referring back to perceived
challenges at previous visit.
Energy-dense food and drinks
Activity and inactivity
Check for queries or areas
of confusion or elaboration
Check for queries or areas
of confusion or elaboration
Check for queries or areas
of confusion or elaboration
Check for queries or areas
of confusion or elaboration
Discuss pedometer data Discuss pedometer data Discuss pedometer data Discuss pedometer data Discuss pedometer data
Personal goals Setting diet or activity
personal goals
Discuss self-monitoring of
personal goals
- Discuss self-monitoring of
personal goals
Discuss self-monitoring of
personal goals
Discuss self-monitoring of
personal goals
Provide positive feedback Provide positive feedback Provide positive feedback Provide positive feedback
Identify new personal goals
or redefine old ones
Identify new personal
goals or redefine old ones
Identify new personal
goals or redefine old ones
Negotiate key long-term
diet and activity goals
based on: perceived
achievements
Summarize success
Identify next appointment Confirm group meeting Identify date for next
appointment
Identify date for motivation
call
Identify last appointment Identify date for
motivation call
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instructed to report any problem or adverse event im-
mediately to the clinical staff.
PADI arm
The intervention will be focused on weight loss combin-
ing a reduced energy intake, an increase of physical ac-
tivity, and reduction of physical inactivity. Women
randomized to this arm will be offered an integrated ver-
sion of both intervention components of the DI and PAI
arms. This integrated approach will be weighted to avoid
intervention overload. Individualized goals will be set for
all participants to promote individualized diet modifica-
tion and individualized physical activity based on indi-
vidual characteristics.
LII arm
Participants included in the LII arm will be considered
as the control group. They will receive general counsel-
ing on health to reduce weight, and be provided with
materials and guidelines available to the general public
[4, 34, 35] and receive two motivational phone calls.
Measures
Weight, and waist and hip circumferences will be mea-
sured at baseline, at 6-, 12-, and 24-month follow-up
visits. Height will be measured at baseline. A fasting
blood sample will be collected at baseline, at 6, and 24
months to measure lipid profile (total, HDL, LDL and
VLDL cholesterol and triglycerides) and estradiol, insu-
lin, glucose, and C-reactive protein level (Table 1).
Body composition will be assessed at baseline and at
6-, 12- and 24-month follow-up visits, using bioelectrical
impedance vector analysis (BIVA) (Nutrilab device,
AKERN Srl, Pontassieve, Italy). BIVA is a more accurate
method for a quick measurement of body compartments
[38, 39]. The direct analysis of the two components of
the impedance vector (Z), resistance (R, Ohm), and
reactance (Xc, Ohm), allows a semiquantitative evalu-
ation of body composition in terms of body cell mass
and hydration status. Data for total body water (TBW),
body cell mass (BCM), extracellular water (ECW), fat-
free mass (FFM), fat mass (FM) and percentage fat mass
(% FM) will be available for all participants and will be
used for identifying changes of fat and fat-free mass over
the study period.
Physical activity will be also measured via the Inter-
national Physical Activity Questionnaire (IPAQ) at base-
line, 6 and 24 months. This questionnaire consists of
questions that record the frequency and duration of mild,
moderate, and strenuous exercise performed during free
time in the previous 7 days measuring physical activity
and inactivity. It is a validated self-report measure of exer-
cise that has been reliably used in previous studies [40].
The total hours per week spent in each activity will be
multiplied by the estimated metabolic cost of each activity
[metabolic equivalent (MET) value] as determined from
the Compendium of Physical Activities [41].
Dietary intake will be measured at baseline, 6 and 24
months using the validated and self-administered food fre-
quency questionnaire (FFQ) developed for the European
Prospective Investigation into Cancer and Nutrition Ital-
ian section (EPIC) study [42, 43]. It records daily intake of
foods and nutrients over the previous year. It consists of
15 sections (first course, second course, side dish, fruit,
etc.) and contains 254 questions investigating a wide range
of food items.
Quality of life (QoL), health status and anxiety will be
measured at baseline, 6-, 12- and 24-month visits using
the Functional Assessment of Cancer Therapy-Breast
(FACT-B) and State-Trait Anxiety Inventory (STAI)
questionnaires. The FACT-B is a 37-item validated
multidimensional self-report questionnaire, subdivided
into four primary QoL domains and a disease-specific
domain – additional concerns for breast cancer [44].
The subscales measure physical, social, emotional, and
functional well-being, relationship with the doctor, and
breast cancer concerns. The FACT-B has a 5-point
Likert-type response scale. It has good psychometric
properties, discriminates well between clinically distinct
groups, and is responsive to change.
The STAI is a psychological inventory based two 20-
item self-report measures. It assesses how respondents
feel “right now, at this moment” and how respondents
“generally feel”. In addition, the STAI State and Trait each
have been found to contain two factors, which Spielberger
labeled anxiety-present and anxiety-absent [45]. Respon-
dents are asked to rate themselves on each item on the
basis of a 4-point Likert scale, ranging from “not at all” to
“very much so” for the STAI State and from “almost
never” to “almost always” for the STAI Trait.
The intervention will propose the use of a pedometer-
like device (a wristband) that encourages both increased
physical activity and decreased sedentary time. This de-
vice is able to record total steps taken, total distance
traveled, total time active during the day, and the great-
est length of time of consistent movements done during
the day. In addition it records light and deep sleeping
time. All participants will receive and will have to wear
the wrist-based activity monitor during the 6-month
study period (days and nights). They could use a smart-
phone or a computer application to obtain feedback on
their activity and sedentary time.
Serious adverse events
We expect a very low risk for participants. We do not
foresee any serious adverse events. However, if partici-
pants do experience an adverse event, this will be
brought immediately to the attention of the clinical staff.
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All participants will be monitored to prevent any pos-
sible deficiency or inadequate nutrient and/or caloric in-
take by means of an evaluation of their dietary intake
(dietary recalls and/or food diaries). Participants will also
be monitored for injuries or problems associated with
increased physical activity.
Statistical considerations
The present study is designed as a mono-institutional,
randomized, controlled four-arm parallel-group trial.
The study will be conducted over a 2-year period, during
which patients will receive a 6-month intervention, and
will be followed until the end of the study period. Study
participants will be randomized to one of the four arms:
Dietary Intervention (DI); Physical Activity Intervention
(PAI); Physical Activity And Dietary Intervention (PADI);
or Less Intensive Intervention (LII). The less intensive (or
minimal) intervention group will be considered as the
control group.
This design is chosen because it has the advantage of
testing single or combined interventions, and of compar-
ing the results with the control group (LII).
The mono-institutional study design will be character-
ized by uniform diagnostic procedures, standard treat-
ment protocols and central pathological evaluation of
surgical specimens, thereby limiting variations in the
determination of major clinical and pathological factors
that determine disease outcome. It will also ensure a
uniform follow-up of patients for the study-specific
endpoint.
The primary outcome measure will be assessed at the
end of the 6-month intervention, by measuring the body
weight. We expect a body weight reduction ≥5 % of the
baseline body weight in all the intervention arms. The
secondary outcome measures will be assessed through
the intervention during the follow-up visits: (a) we ex-
pect weight control over the study period, measuring the
body weight at each follow-up visit; (b) we expect an in-
crease in physical activity levels and reduction in physical
inactivity from baseline measured by the pedometer-like
devices and from the IPAQ questionnaire. The physical
activity target for improving general health is 30 minutes
of moderate-to-vigorous intensity every day (equivalent to
10 MET-hours per week) and reducing inactivity; (c) we
expect a change in dietary intake and an increased adher-
ence to healthy diet from baseline using the FFQ; (d) we
will evaluate the effect of the intervention on long-term
breast cancer recurrence; (e) we expect an improvement
in quality of life and in health status from baseline using
the FACT-B and STAI; (f) we will evaluate the effect of
intervention on the blood lipid profile. We expect an
increase in HDL cholesterol and a decrease in LDL
cholesterol, triglycerides and total cholesterol; (g) we will
evaluate the effect of intervention on some biomarkers:
estradiol, CRP, insulin, and glucose. Statistical analyses will
only be carried out after the end of the trial, with no in-
terim analysis planned.
Sample size
During 2012, 756 overweight or obese women (with a
BMI comprising between 25 and 40 kg/m2) underwent
surgery for early-stage (non-metastatic) breast cancer at
the European Institute of Oncology. Data for these
patients were retrieved from our institutional breast can-
cer patients’ database. The mean weight of these 756
patients was 75 kg and the standard deviation was 9.
The sample size calculation was based on a superiority
design of any single intervention (DI, PAI, or PADI)
compared to the control group (LII). A sample group of
65 patients (control group) and similar number in any of
the three intervention groups (diet and/or exercise) for a
total of 195 patients achieve 80 % power to detect a 5 %
weight loss (3.75 kg) between the null hypothesis that
both group means are 75 kg and the alternative hypoth-
esis that the mean of any of the intervention group 2 is
71.25 after 6 months, with known group standard devia-
tions of 9.0 and 9.0 and with a significance level (alpha)
of 0.05 using a two-sided two-sample t test. We have
foreseen a drop-out of 5 % over the first 6 months.
Statistical methods
All continuous variables (anthropometric, biomedical,
nutritional and psychological measurements) at baseline
and at the primary time point (6-month) will be checked
for normality and transformed as needed. The Student t
test, analysis of covariance (ANCOVA) and multiple lin-
ear regression models will be used to assess changes in
means before and after the intervention. All tests will be
two-sided and P values <0.05 will be considered statisti-
cally significant.
Dissemination policy
The final report will be presented at the Associazione
Italiana per la Ricerca sul Cancro (AIRC). Trial results
will be communicated to participants organizing a dedi-
cated event. Results will be also communicated in peer-
reviewed journals, in national and international scientific
conference, and to the public via press release.
Data collection, storage and security
All data collected on the questionnaires and all relevant
information about the participants will be uploaded on
dedicated electronic databases. All forms must be filled
in by the researcher or by a person delegated by the re-
searcher. Data will be held according to the International
Conference on Harmonisation (ICH) Good Clinical Prac-
tice (GCP) E6 Guideline and the Declaration of Helsinki
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and will be treated with confidentiality, following the
current privacy policy [46].
Fully anonymized data from the EPIC food frequency
questionnaire will be uploaded on a dedicated online
database [47] for the conversion of the FFQ data into a
list of food-group and nutrient intake. Data recorded by
the pedometer device will be downloaded on a dedicated
application [48] adopting security measures to protect
personal information [49]. Fully anonymized data will be
conveyed periodically to researchers and saved to a
password-protected server.
Registration
The trial is registered with ClinicalTrials.gov, number
NCT02622711 (registration date: 2 December 2015) and
with ISRCTN registry, number ISRCTN53325751 (regis-
tration date: 16 October 2015).
Discussion
We presented the protocol of a 6-month intervention
trial focused on weight loss in a group of overweight or
obese women previously treated for early breast cancer.
This trial will provide important insights regarding the
effect of an intervention carried out in Italy which is
designed to improve adherence to a healthy diet and/or
to increase physical activity and decrease sedentary
time, taking advantage of a pedometer device. Despite
the increasing number of trials of weight loss interven-
tions in breast cancer, so far only the DIANA (DIet and
ANdrogens) randomized controlled trials have been
undertaken on cancer survivors in Italy. They studied
the effect of a Mediterranean-macrobiotic lifestyle on
breast cancer patients [50] and found a 10 % reduction
of testosterone level [50] and an improvement of car-
diopulmonary functional capacity and vascular endo-
thelial function following a moderate intensity exercise
training combined with the macrobiotic diet [51]. The
most recent extension of the DIANA trial [52] is ongoing.
It is a two-arm intervention to promote dietary change
and a moderate increase in physical activity aimed at de-
creasing circulating hormone concentrations, breast can-
cer recurrences, and improving survival.
Our study, with its multi-arm design, has the advantage
of evaluating the effect on participants by comparing three
different approaches to a common control arm or com-
bining the effect of the interventions. It also appears more
appealing to patients because it provides an increased
probability of receiving an experimental intervention ra-
ther than the control treatment. The educational compo-
nents of our intervention will be based on national [35]
and international recommendations [4], promoting the
Mediterranean diet, which includes many dietary features
that have been shown to promote health [53]. The sched-
uled visits and the motivational interviewing approach
chosen should ensure a more active role of the patients in
lifestyle change to achieve success. Motivational interview-
ing aims to enhance self-efficacy and personal control for
behavior change. It uses an interactive, empathic listening
style to increase motivation and confidence, emphasizing
the discrepancy between personal goals and health behav-
iors [54]. Moreover our project will take advantage of a
pedometer device to quantify ambulatory activity during
walking and running, by means of a common and easily
understood metric (i.e., steps). This device is appealing
since it objectively monitors physical activity and can be
an important means for providing behavioral feedback
and motivation. Pedometer-based walking interventions
have demonstrated their effectiveness in increasing phys-
ical activity in adult populations [55–57]. Objective meas-
uring changes in physical activity in addition to a standard
measurement (questionnaire) can add further precision to
the physical activity level reached by participants during
the intervention.
Due to the increasing concern on the role of obesity in
cancer survival and recurrence [11], there is the need for
evidence regarding the most effective approach in
promoting weight control and the adoption of a healthy
lifestyle in breast cancer survivors. The results of this
innovative project will provide useful information for fu-
ture interventions and potentially have a large public
health impact on breast cancer survivors.
Trial status
Recruitment started in November 2015 and is ongoing.
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